The association of exercise test variables with long-term mortality in patients with chronic Chagas disease.
Chagas disease
VO2max
maximal functional capacity
mortality
prognosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
06
2022
accepted:
22
08
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
epublish
Résumé
The identification of variables obtained in the exercise test (ET) associated with increased risk of death is clinically relevant and would provide additional information for the management of Chagas disease (CD). The objective of the present study was to evaluate the association of ET variables with mortality in patients with chronic CD. This retrospective longitudinal observational study included 232 patients (median age 46.0 years; 50% women) with CD that were followed at the Evandro Chagas National Institute of Infectious Diseases (Rio de Janeiro, Brazil) and performed an ET between 1989 and 2000. The outcome of interest was all-cause mortality. There were 103 deaths (44.4%) during a median follow-up of 21.5 years (IQR 25-75% 8.0-27.8), resulting in 24.5 per 1,000 patients/year incidence rate. The ET variables associated with mortality after adjustments for potential confounders were increased maximal (HR 1.02; 95% CI 1.00-1.03 per mmHg) and change (HR 1.03; 95% CI 1.01-1.06 per mmHg) of diastolic blood pressure (DBP) during ET, ventricular tachycardia at rest (HR 3.95; 95% CI 1.14-13.74), during exercise (HR 2.73; 95% CI 1.44-5.20), and recovery (HR 2.60; 95% CI 1.14-5.91), and premature ventricular complexes during recovery (HR 2.06; 1.33-3.21). Our findings suggest that ET provides important prognostic value for mortality risk assessment in patients with CD, with hemodynamic (increased DBP during exercise) and electrocardiographic (presence of ventricular arrhythmias) variables independently associated with an increased mortality risk in patients with CD. The identification of individuals at higher mortality risk can facilitate the development of intervention strategies (e.g., close follow-up) that may potentially have an impact on the longevity of patients with CD.
Sections du résumé
Background
UNASSIGNED
The identification of variables obtained in the exercise test (ET) associated with increased risk of death is clinically relevant and would provide additional information for the management of Chagas disease (CD). The objective of the present study was to evaluate the association of ET variables with mortality in patients with chronic CD.
Methods
UNASSIGNED
This retrospective longitudinal observational study included 232 patients (median age 46.0 years; 50% women) with CD that were followed at the Evandro Chagas National Institute of Infectious Diseases (Rio de Janeiro, Brazil) and performed an ET between 1989 and 2000. The outcome of interest was all-cause mortality.
Results
UNASSIGNED
There were 103 deaths (44.4%) during a median follow-up of 21.5 years (IQR 25-75% 8.0-27.8), resulting in 24.5 per 1,000 patients/year incidence rate. The ET variables associated with mortality after adjustments for potential confounders were increased maximal (HR 1.02; 95% CI 1.00-1.03 per mmHg) and change (HR 1.03; 95% CI 1.01-1.06 per mmHg) of diastolic blood pressure (DBP) during ET, ventricular tachycardia at rest (HR 3.95; 95% CI 1.14-13.74), during exercise (HR 2.73; 95% CI 1.44-5.20), and recovery (HR 2.60; 95% CI 1.14-5.91), and premature ventricular complexes during recovery (HR 2.06; 1.33-3.21).
Conclusion
UNASSIGNED
Our findings suggest that ET provides important prognostic value for mortality risk assessment in patients with CD, with hemodynamic (increased DBP during exercise) and electrocardiographic (presence of ventricular arrhythmias) variables independently associated with an increased mortality risk in patients with CD. The identification of individuals at higher mortality risk can facilitate the development of intervention strategies (e.g., close follow-up) that may potentially have an impact on the longevity of patients with CD.
Identifiants
pubmed: 36203775
doi: 10.3389/fmed.2022.972514
pmc: PMC9530636
doi:
Types de publication
Journal Article
Langues
eng
Pagination
972514Informations de copyright
Copyright © 2022 Silva, Mendes, Fleg, Rodrigues Junior, Vieira, Xavier, Costa, Reis, Mazzoli-Rocha, Costa, Holanda, Veloso, Sperandio da Silva, Sousa, Saraiva, Hasslocher-Moreno and Mediano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br Heart J. 1995 Sep;74(3):293-5
pubmed: 7547025
Am J Cardiol. 1979 Apr;43(4):708-12
pubmed: 425905
Int J Cardiol. 2008 Jul 21;127(3):372-9
pubmed: 17689706
Rev Soc Bras Med Trop. 2021 Jun 02;54:e00402021
pubmed: 34105626
Mem Inst Oswaldo Cruz. 2018 Aug 20;113(10):e180224
pubmed: 30133549
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60
pubmed: 27982292
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
Am J Hypertens. 2018 Aug 3;31(9):976-980
pubmed: 29767671
Lancet Infect Dis. 2013 Apr;13(4):342-8
pubmed: 23395248
J Chronic Dis. 1971 Oct;24(9):519-22
pubmed: 5158764
Lancet. 2018 Jan 6;391(10115):82-94
pubmed: 28673423
Circulation. 1987 Jun;75(6):1140-5
pubmed: 3552307
Trans R Soc Trop Med Hyg. 1990 Nov-Dec;84(6):787-91
pubmed: 2128980
Am Heart J. 1973 Apr;85(4):546-62
pubmed: 4632004
Rev Soc Bras Med Trop. 2015 Jan-Feb;48(1):4-10
pubmed: 25714933
J Am Coll Cardiol. 2013 Aug 13;62(7):595-600
pubmed: 23747767
Circulation. 2012 Jun 12;125(23):2836-43
pubmed: 22572915
J Am Coll Cardiol. 2016 Feb 23;67(7):780-9
pubmed: 26892413
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2410
pubmed: 24069473
Rev Esp Cardiol. 2010 Jul;63(7):788-97
pubmed: 20609312
Arq Bras Cardiol. 2010;95(5 Suppl 1):1-26
pubmed: 21340292
Arch Intern Med. 2008 Jan 28;168(2):225-34
pubmed: 18227372
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Circulation. 2011 Jan 18;123(2):216-25
pubmed: 21242508
Rev Soc Bras Med Trop. 2020;53:e20200100
pubmed: 32638887
J Hum Hypertens. 2003 Mar;17(3):153-8
pubmed: 12624604
Parasit Vectors. 2016 Jan 27;9:42
pubmed: 26813568
Circulation. 1994 Dec;90(6):3098-102
pubmed: 7994859
N Engl J Med. 1999 Oct 28;341(18):1351-7
pubmed: 10536127
J Sports Med (Hindawi Publ Corp). 2016;2016:3968393
pubmed: 28116349
Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):421-426
pubmed: 30133623
JAMA. 2003 Sep 24;290(12):1600-7
pubmed: 14506119
J Am Heart Assoc. 2020 Jan 7;9(1):e014547
pubmed: 31902329
JAMA. 1999 Feb 10;281(6):524-9
pubmed: 10022108
N Engl J Med. 2006 Aug 24;355(8):799-808
pubmed: 16928995
Int J Cardiol. 2013 Oct 9;168(4):4584-5
pubmed: 23871619
Circulation. 1960 Jun;21:1160-75
pubmed: 13849070
Qual Life Res. 2019 Jan;28(1):67-72
pubmed: 30167935
N Engl J Med. 2003 Feb 27;348(9):781-90
pubmed: 12606732
Pacing Clin Electrophysiol. 2011 Nov;34(11):1492-7
pubmed: 21797898
Am Rev Respir Dis. 1985 May;131(5):700-8
pubmed: 3923878